comprehensive -WSS

comprehensive

author：entertainment 2025-09-30 11:07:06 - browse：727

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

The Danish pharmaceutical company Novo Nordisk has shepherded all kinds of medical innovation in the 110 years since it was founded. But the booming success of its diabetes and obesity drug is unlike anything executives have seen before.

The company’s mid-year operating profit jumped from 37.5 billion Danish kroner in 2022 to 48.9 billion Danish kroner this year — “probably the strongest growth in the history of the company,” Chief Financial Officer Karsten Munk Knudsen said during an August earnings call. The 30% growth rate came from sales of semaglutide, which Novo Nordisk sells for diabetes under the name Ozempic and for obesity as Wegovy.

With its new blockbuster drug in hand, Novo Nordisk is valued higher than the entire economy of Denmark, where it’s based.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Watch the official trailer for 'Ahsoka' series

entertainment

WSS

Iran's president begins a rare visit to Africa 'to promote economic diplomacy'

Will generative AI in health care meet the fate of IBM's Dr. Watson?

The Readout: Lenmeldy, GLP

There's no autism epidemic. It's an autism diagnosis epidemic

Women's World Cup brings attention to abuse in soccer

Oprah kicked off a national conversation on obesity. Let's have it

leisure time

comprehensive

focus

Dobbs anniversary: the lost opportunity of abortion as health care

Grail's uphill battle for Medicare to cover its cancer screening test

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

States should stop sabotaging methadone treatment reform

Apple is now the first public company to be valued at $3 trillion

Primary care physicians play key roles in Alzheimer's management

Moonlake's readout produced a cash windfall. Risks remain

Readout Newsletter: Blackstone Life Sciences, Merck, Bluebird Bio

How to save PrEP access — and even expand it

Grail's uphill battle for Medicare to cover its cancer screening test

hotspot

States should stop sabotaging methadone treatment reform

Antibody drugs appear effective. Now can we make enough of them?

EU fines Illumina $475 million over Grail acquisition

A Greenpeace activist is fined for crash

Washington mulls new rules to avert another Change Healthcare

Russia's threat to pull out of Ukraine grain deal raises fears about global food security

focus

entertainment

hotspot

explore